- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Waldenstrom Macroglobulinemia, Lymphocytosis, Lymphoma, Non-Hodgkin, B-Cell Chronic Lymphocytic Leukemia, Hematological Malignancies
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–86
of 86
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COVID-19, Influenza
- Interventions
- Lucira COVID-19 & Flu Test
- Device
- Lead sponsor
- Lucira Health Inc
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 1,361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Cullman, Alabama • Colton, California • Oakland, California + 4 more
- Conditions
- Influenza, Human
- Interventions
- MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV), Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1), MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)
- Biological
- Lead sponsor
- Seqirus
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 1,778 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 20
- States / cities
- Mobile, Alabama • Anaheim, California • Redding, California + 17 more
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B
- Interventions
- Aptitude Medical Systems Metrix COVID/Flu Test
- Diagnostic Test
- Lead sponsor
- Aptitude Medical Systems
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Trussville, Alabama • Goleta, California • Chelmsford, Massachusetts
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Interventions
- Panbio™
- Diagnostic Test
- Lead sponsor
- Abbott Rapid Dx
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Influenza, Human
- Interventions
- Zanamivir, Placebo to match zanamivir, Oseltamivir, Placebo to match oseltamivir
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more
- Conditions
- Influenza, Human, COVID-19, Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Interventions
- Not listed
- Lead sponsor
- Evidation Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18,157 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- San Mateo, California
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection
- Interventions
- The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
- Diagnostic Test
- Lead sponsor
- Thermo Fisher Scientific, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,909 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 17
- States / cities
- San Diego, California • Lake City, Florida • Miami, Florida + 13 more
- Conditions
- Influenza, Influenza Immunisation
- Interventions
- Influenza Virus Vaccine Inactivated
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Interventions
- Panbio™
- Diagnostic Test
- Lead sponsor
- Abbott Rapid Dx
- Industry
- Eligibility
- Not listed
- Enrollment
- 903 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Easley, South Carolina
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- fludarabine phosphate, melphalan, nonmyeloablative allogeneic hematopoietic stem cell transplantation, intensity-modulated radiation therapy, tomotherapy, total marrow irradiation, total nodal irradiation
- Drug · Procedure · Radiation
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Respiratory Tract Infections
- Interventions
- Respiratory pathogen panel PCR test, COVID-19 antibody test
- Diagnostic Test
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1, Parainfluenza Type 2, Parainfluenza Type 3, Parainfluenza Type 4, Human Metapneumovirus A/B, Rhinovirus, Coxsackie Virus/Echovirus, Adenovirus Types B/C/E, Coronavirus Subtypes 229E, Coronavirus Subtype NL63, Coronavirus Subtype OC43, Coronavirus Subtype HKU1, Human Bocavirus, Artus Influenza A/B RT-PCR Test, Influenza B
- Interventions
- artus Influenza A/B RT-PCR Test
- Device
- Lead sponsor
- QIAGEN Gaithersburg, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 5
- States / cities
- Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more
- Conditions
- Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin, Lymphoblastic Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult
- Interventions
- Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam, Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells, Thymoglobulin, Cyclophosphamide
- Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota